GluBio Therapeutics

GluBio Therapeutics Inc. ("GluBio") is a biotechnology company dedicated to the discovery and development of novel molecular glue degraders (MGDs), with a mission to address unmet clinical needs across oncology, autoimmune diseases, and genetic disorders, etc. The founders and core team members possess extensive experience in molecular glue drug discovery and management. Since its establishment in March 2021, the company has secured funding from top-tier investors, including Hillhouse Capital, Qiming Venture Partners, Lilly Asia Ventures, Kaitai Capital, Legend Capital, K2VC, E Fund Capital and Sanofi.

As a leader in the field, GluBio leverages its proprietary Glue Degrader Discovery (GDD©) platform to drive systematic innovation. The company has built an integrated R&D engine comprising an innovative target identification and validation, a multi-dimensional protein degradation screening, a rational molecular glue design, and a diverse proprietary compound library.

GluBio focuses on developing molecular glue degraders with “first-in-class” and “best-in-class” potential. All pipeline programs are independently developed and protected by global intellectual property rights. Notably, two novel molecular glue degraders, GLB-001 and GLB-002, have already entered clinical-stage studies both in the U.S. and China.